The way these pharmacies have assumed a outstanding position in this projected $100 billion marketplace—providing corporations with drugs, for example oral GLP-1s, that are not FDA-authorised—warrants closer examine. “We’ve observed an especially good response from our prospects,” he suggests. “No untoward Uncomfortable side effe